Naslov
Agents acting on renin-angiotensin system: the impact of generics and price trends in Croatia

Autori
Kučan, Marta ; Mršić-Pelčić, Jasenka ; Mance, Diana ; Vitezić, Dinko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Clinical Therapeutics / - , 2015, E71-e71

Skup
12th Congress of the European Association for Clinical Pharmacology and Therapeutics

Mjesto i datum
Madrid, Španjolska, 27.06.2015. - 30.06.2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
cardiovascular therapy ; renin-angiotensin system ; generics ; price trends

Sažetak
Adequate cardiovascular therapy that includes usage of Agents acting on renin-angiotensin system (RAS), (ATC, C09) results in the reduction of cardiovascular morbidity and mortality. It is important to establish measures for higher usage of cheaper generics which will lead to the reduction of the healthcare costs. The aim of our study was to identify and analyse changes in the usage of original and generics drugs in RAS subgroup agents in Croatia from 2000-2013 and to identify the rate of the generic drugs usage as well as the average price for 1 DDD. Data on the consumption have been obtained from the database IMS (International Medical Statistics) for Croatia. According to the World Health Organization Collaborating Centre for Drugs Statistics Methodology annual volumes of drugs are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while drug costs data are presented in Euro per DDD. The usage of original drugs increased from 5.86 DDD/1000/day to 63.56 during the investigated period and generics increased from 52.70 to 136.32. Consumption share of generics decreased from 90% in 2000 to 56% in 2006, and then we had constant increase to 68% in 2013. Average price of 1 DDD for both original and generic drugs in C09 subgroup decreased in total from 0.31 EUR/DDD in 2000 to 0.16 EUR/DDD in 2013, which is decrease of 48.91% (39.42% for originals, and 55.57% for generics). The national healthcare policy promoting generics resulted in their increase of usage up to 2013, but due to the introduction of new INNs in subgroup (Angiotensin II antagonists, plain and combinations) it was less obvious then expected. The price trend showed price decrease in originals and generics as a result of price reduction policy introduced by Croatian National Insurance Company, but it is necessary to introduce new measures for further generic promotion.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA